• Identify comorbid risk factors for MS progression in order to apply appropriate strategies
• Review efficacy and safety data for current and emerging DMT agents for MS

FACULTY
Michael Levy, MD, PhD
Associate Professor, Harvard Medical School
Director, Neuroimmunology Clinic and Research Laboratory
Research Director, Division of Neuroimmunology & Neuroinfectious Disease
Department of Neurology, Massachusetts General Hospital
Boston, Massachusetts

PLANNING COMMITTEE

Michael Levy, MD, PhD
Associate Professor, Harvard Medical School
Director, Neuroimmunology Clinic and Research Laboratory
Research Director, Division of Neuroimmunology & Neuroinfectious Disease
Department of Neurology, Massachusetts General Hospital
Boston, Massachusetts

Margaret Das, PhD
Senior Medical Writer
The France Foundation
Old Lyme, Connecticut

June Halper, MSN, APN-C, MSCN, FAAN, CEO, CMSC, IOMSN
Chief Executive Officer, CEO
Consortium of Multiple Sclerosis Centers (CMSC)
International Organization of Multiple Sclerosis Nurses (IOMSN)
Hackensack, New Jersey

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physicians

The Consortium of Multiple Sclerosis Centers designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The Consortium of Multiple Sclerosis Centers designates this activity for 0.50 nursing continuing professional development (NCPD) credits (0.5 of these credits are in the area of pharmacology).

All other healthcare professionals completing this course will be issued a statement of participation.

PHYSICIAN ASSISTANTS

The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 05/02/24. PAs should only claim credit commensurate with the extent of their participation.

PHARMACISTS

This knowledge-based activity, UAN JA4008165-9999-23-016-H01-P, qualifies for 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity CMSC and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, CMSC and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

CMSC and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from Novartis.

Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission